Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Obinutuzumab (GA101) is a novel glycoengineered type II CD20 antibody in development for non-Hodgkin lymphoma. We compared the anti-tumor activity of obinutuzumab and rituximab in preclinical studies using subcutaneous Z138 and WSU-DLCL2 xenograft mouse models. Obinutuzumab and rituximab were assess...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Herting, Frank, Friess, Thomas, Bader, Sabine, Muth, Gunter, Hölzlwimmer, Gabriele, Rieder, Natascha, Umana, Pablo, Klein, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: Informa Healthcare 2014
Assuntos:
Original Article: Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196549/
https://ncbi.nlm.nih.gov/pubmed/24304419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.856008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados